Weekly Roundup: April 3–9, 2020


More from:

This roundup contains a collection of the posts published on the Forum during the week of April 3–9, 2020

SEC–Exempt Offerings


Executive Compensation Programs & COVID-19




COVID-19 as a Material Adverse Effect (MAC) Under M&A and Financing Agreements


Federal Forum Selection Bylaws for Securities Act Claims



The Atmosphere for Climate-Change Disclosure


Rewriting the Poison Pill Prescription: Consider Active Defenses During COVID-19


Postponing/Adjourning Annual Meetings Following COVID-19



Federal Forum Provision Possible Impact on D&O Insurance




Thoughts for Boards of Directors in the COVID19 Crisis


Fiduciary Duties During a Time of Volatility


ESG Disclosures and Litigation Concerns


Corp Fin Disclosure Guidance: Topic No. 9 Coronavirus


Director Oversight in the Context of COVID-19


Purchasing Portfolio Company Debt—Threshold Issues for Private Equity Sponsors


Proactively Adopting a Poison Pill in Response to the COVID-19 Crisis


Accounting Class Action Filings and Settlements: 2019 Review and Analysis


Annual General Meetings & COVID-19


Are Corporate Payouts Abnormally High in the 2000s?


A Turn Back to “Poison Pills” in Response to the Coronavirus Pandemic


More from:
Trackbacks are closed, but you can post a comment.

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>